grant

Revealing the Biophysics of the Germinal Center Microenvironment

Organization UNIVERSITY OF TEXAS MED BR GALVESTONLocation GALVESTON, UNITED STATESPosted 22 Dec 2021Deadline 30 Nov 2026
NIHUS FederalResearch GrantFY2026A2ARADORA2ADORA2A geneAIDS VaccinesAIDS VirusAIDS vaccineAchievementAchievement AttainmentAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAddressAdenosineAdenosine A(2A) ReceptorAdenosine A2A ReceptorAdenosine ReceptorsAffectAffinityAnimal ModelAnimal Models and Related StudiesAntibodiesAntibody ResponseAntigenic DeterminantsAntigensAutoimmune StatusAutoimmunityAvidityB blood cellsB cellB cell receptorB cellsB-Cell ActivationB-Cell Antigen ReceptorB-CellsB-LymphocytesB-cellBinding DeterminantsBiologic ModelsBiological ModelsBiologyBiophysicsCell Communication and SignalingCell Culture TechniquesCell SignalingCell modelCellular biologyCellular modelCharacteristicsClone CellsCoinComplexCuesDrug TherapyEngineeringEnv trimerEpitopesEventExtracellular SpaceFrequenciesFutureG Protein-Complex ReceptorG Protein-Coupled Receptor GenesG-Protein-Coupled ReceptorsGPCRGenerationsGenesGerm LinesGerminal CenterGoalsHIVHIV EnvHIV SeronegativitiesHIV SeronegativityHIV envelopeHIV envelope proteinHIV glycoprotein EnvHIV individualsHIV infected individualsHIV infected personsHIV negativeHIV peopleHIV positive individualsHIV positive peopleHIV vaccineHIV-1 EnvHIV-1 envelopeHIV-1 glycoprotein EnvHIV/AIDS VaccinesHTLV-III SeronegativitiesHTLV-III SeronegativityHelper CellsHelper T-CellsHelper T-LymphocytesHelper-Inducer T-CellsHelper-Inducer T-LymphocyteHumanHuman Immunodeficiency VirusesHypoxiaHypoxicHypoxic tumorIg Somatic HypermutationImmune responseImmunizationImmunochemical ImmunologicImmunoglobulin Somatic HypermutationImmunologicImmunologicalImmunologicallyImmunologicsImmunomodulationIn VitroIndividualInducer CellsInducer T-LymphocytesInfluenza HAInfluenza HemagglutininIntercellular SpaceIntracellular Communication and SignalingIslandKnowledgeLAV-HTLV-IIILearningLicensingLymphadenopathy-Associated VirusMeasurementMeasuresMetabolicMetabolic PathwayMiceMice MammalsMicrodialysisMicroscopicModel SystemModelingModern ManMurineMusMutateNatureOutcomeOxygen DeficiencyP1 PurinoceptorsP50 MechanismP50 ProgramPLWHPWHPathway interactionsPharmacological TreatmentPharmacotherapyPhasePhylogenetic AnalysisPhylogeneticsPhysiologicPhysiologicalPlayPopulationPurinergic P1 ReceptorsRDC8ReactionRoleSeriesSignal TransductionSignal Transduction SystemsSignalingSpecialized CenterStructureStructure of germinal center of lymph nodeSystemTemperatureVEGFVEGFsVaccinationVaccine AntigenVaccine DesignVaccinesVascular Endothelial Growth FactorsVirusVirus-HIVWorkactivated B cellsbiological signal transductionbiophysical characteristicsbiophysical characterizationbiophysical foundationbiophysical measurementbiophysical parametersbiophysical principlesbiophysical propertiesbiophysical sciencescancer microenvironmentcell biologycell culturecell culturesdesigndesigningdrug interventiondrug treatmentextracellularfitnessflu HAflu hemagglutininhost responsehuman immunodeficiency virus vaccineimmune modulationimmune regulationimmune response to vaccinationimmune response to vaccinesimmune system responseimmunogenimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimprovedindividuals infected with HIVindividuals with HIVindividuals with human immunodeficiency virusinfluenza viral HAinfluenza viral hemagglutinininfluenza virus HAinfluenza virus hemagglutinininsightinterestmodel of animalmulti-photonneutralizing antibodynovelpathwaypeople infected with HIVpeople infected with human immunodeficiency viruspeople living with HIVpeople with HIVpeople with human immunodeficiency viruspharmaceutical interventionpharmacologicpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspressurepublic health interventionrecruitresponsesmall moleculesocial rolesomatic hypermutationsuccesstumor hypoxiatumor microenvironmentvaccine against HIVvaccine associated immune responsevaccine immune responsevaccine immunogenicityvaccine induced immune response
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Abstract
Is an HIV vaccine possible? Vaccines are one of the most successful public health interventions over the past

century. Nearly all vaccines work by induction of protective antibodies. However, our understanding of the cellular

dynamics of immune responses to vaccines, particularly the biology surrounding B cell competition within

germinal centers (GC) to complex vaccine antigens is limited. This lack of understanding of fundamental B cell

biology has contributed to the inability to develop an effective HIV vaccine. Promisingly, a small population of

HIV+ individuals have developed broadly neutralizing antibodies (bnAbs), giving renewed hope that an HIV

vaccine is possible. Recent work has found that many HIV negative healthy human donors have VRC01-class

bnAb precursor B cells. However, work from these studies revealed that these potential bnAb precursor B cells

are found at an unusually rare frequency. This suggested that following immunization these B cells may be

outcompeted by more frequent non-neutralizing B cells. To answer immunological questions surrounding this

problem, I developed a model system utilizing mice containing human genes for the germline-reverted VRC01

bnAb (VRC01gHL). Through this B cell transfer model, we found that antigen affinity, avidity, and precursor

frequency all played interdependent roles in competitive success of rare VRC01gHL B cells in GCs. Critically, we

found that rare VRC01gHL B cells with physiological affinities could be primed to successfully compete within

GCs. However, these responses were limited to specific “GC” islands suggesting B cell competition to seed

individual GCs is critical in addition to competition within the GC. Taken together, these observations suggest

that B cell immunodominance in the GC microenvironment (GCME) is a major obstacle to overcome in

developing a successful HIV vaccine. However, there are significant knowledge gaps pertaining to the

physiological conditions in which B cells compete to enter GCs, and compete within the GCME. To start, what

do we know about the biophysical and metabolic characteristics of the GCME? We hypothesized and found that

GCs form a hypoxic microenvironment. I hypothesize that other biophysical constraints may be acting to control

GC selection events as many pathways have been shown to be both active in hypoxic tumor microenvironments

(TMEs) and in the hypoxic GCME. I hypothesize that in further correlation with TMEs, the GCME may contain

high lactate levels, induce multiple metabolic GPCRs, reduced pH, increased temperature, and cellular pressure.

I posit that these biophysical parameters of the GC can and do influence B cell selection events to complex

antigens. In this DP2 proposal I will investigate the nature of the extracellular milieu of the GCME through multi-

photon targeted direct measurements and define the biophysical constraints that limit the success of VRC01-

class B cell responses. We will then apply what we learn from studying the GCME to manipulate B cell

immunodominance in the GCME to favor competitive selection of VRC01-class B cells.

Grant Number: 5DP2AI154410-05
NIH Institute/Center: NIH

Principal Investigator: Robert Abbott

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →